TNF and inflammatory bowel disease: Although meta-analysis exists comparing the effects of adalimumab and infliximab dose escalation, no study has yet provided a comparative analysis of these therapies specifically in IBD patients who required dose escalation due to failure of first-line anti-TNF-α therapy.